Skip to main content Skip to navigation
Hamburger Menu
Search icon
Country Selector Country Selector
India (English)
Profile Icon Profile Icon
Sign-in/Register UserName
Discover & Learn

Resources & Tools

Products

Discover & Learn

Resources & Tools

Support

Search icon Search icon
Close Menu
      Alert Icon
      TITLE 2 APPS AND SOLS FREE FORM TEST FEATURES AND SPECS TEXT AND DOWNLOAD SECTION TESTIMONIAL TEXT AND IMAGE
      TITLE 2

      Title

      Sub title
      1. Point with number
      • Point with bullet
      performance1

      APPS AND SOLS

      Applications and Solutions

      Content1
      • Description 1
      • Description 2
      • Description 3
      • Description 4
      • Description 5
      1. Desc 1
      2. Desc 2
      3. Desc 3

       

       
      Test title 2

      Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
      Accordion section
      Accordion title
      Accordion sub title

      • Section description

      • Second desc

      Description for checking the image alignment

       

      apps1

      trial123

      apps1

      trial123

      apps1
      apps1

      ASR Table Clinical

      Measures Reagents Mechanisma Technology
      Wang F, et al. The laboratory tests and host immunity of COVID-19 patients with different severity of illness. JCI Insight. 2020 May;5(10):e137799. doi: 10.1172/jci.insight.137799 21 COVID‑19 Patients Extremely Severe vs Severe vs Moderate Cases Total lymphocytes, total CD4+ and CD8+ T cells, B cells (absolute count) Total T cells, CD4+ cells (%) CD45RA+ Naïve Tregs (%) CD4+ CD28+ and CD8+ CD28+ T cells (%) CD86+ Dendritic cells (%) Total lymphocytes, total CD4+ and CD8+ T cells, B cells (absolute count) Total T cells, CD4+ cells (%) CD45RA+ Naïve Tregs (%) CD4+ CD28+ and CD8+ CD28+ T cells (%) CD86+ Dendritic cells (%)
      Wang F, et al. The laboratory tests and host immunity of COVID-19 patients with different severity of illness. JCI Insight. 2020 May;5(10):e137799. doi: 10.1172/jci.insight.137799 65 COVID‑19 Patients Extremely Severe vs Severe vs Moderate Cases Total lymphocytes, total CD4+ and CD8+ T cells, B cells (absolute count) Total T cells, CD4+ cells (%) CD45RA+ Naïve Tregs (%) CD4+ CD28+ and CD8+ CD28+ T cells (%) CD86+ Dendritic cells (%)
      Wang F, et al. The laboratory tests and host immunity of COVID-19 patients with different severity of illness. JCI Insight. 2020 May;5(10):e137799. doi: 10.1172/jci.insight.137799 21 COVID‑19 Patients Extremely Severe vs Severe vs Moderate Cases Total lymphocytes, total CD4+ and CD8+ T cells, B cells (absolute count) Total T cells, CD4+ cells (%) CD45RA+ Naïve Tregs (%) CD4+ CD28+ and CD8+ CD28+ T cells (%) CD86+ Dendritic cells (%)
      Wang F, et al. The laboratory tests and host immunity of COVID-19 patients with different severity of illness. JCI Insight. 2020 May;5(10):e137799. doi: 10.1172/jci.insight.137799 65 COVID‑19 Patients Extremely Severe vs Severe vs Moderate Cases Total lymphocytes, total CD4+ and CD8+ T cells, B cells (absolute count) Total T cells, CD4+ cells (%) CD4+ CD28+ and CD8+ CD28+ T cells (%) CD86+ Dendritic cells (%)
      Wang F, et al. The laboratory tests and host immunity of COVID-19 patients with different severity of illness. JCI Insight. 2020 May;5(10):e137799. doi: 10.1172/jci.insight.137799 21 COVID‑19 Patients Extremely Severe vs Severe vs Moderate Cases Total lymphocytes, total CD4+ and CD8+ T cells, B cells (absolute count) Total T cells, CD4+ cells (%) CD45RA+ Naïve Tregs (%) CD4+ CD28+ and CD8+ CD28+ T cells (%) CD86+ Dendritic cells (%)
      Wang F, et al. The laboratory tests and host immunity of COVID-19 patients with different severity of illness. JCI Insight. 2020 May;5(10):e137799. doi: 10.1172/jci.insight.137799 65 COVID‑19 Patients Extremely Severe vs Severe vs Moderate Cases Total lymphocytes, total CD4+ and CD8+ T cells, B cells (absolute count) Total T cells, CD4+ cells (%) CD4+ CD28+ and CD8+ CD28+ T cells (%) CD86+ Dendritic cells (%)
      Wang F, et al. The laboratory tests and host immunity of COVID-19 patients with different severity of illness. JCI Insight. 2020 May;5(10):e137799. doi: 10.1172/jci.insight.137799 21 COVID‑19 Patients Extremely Severe vs Severe vs Moderate Cases Total lymphocytes, total CD4+ and CD8+ T cells, B cells (absolute count) Total T cells, CD4+ cells (%) CD4+ CD28+ and CD8+ CD28+ T cells (%) CD86+ Dendritic cells (%)
      Wang F, et al. The laboratory tests and host immunity of COVID-19 patients with different severity of illness. JCI Insight. 2020 May;5(10):e137799. doi: 10.1172/jci.insight.137799 65 COVID‑19 Patients Extremely Severe vs Severe vs Moderate Cases Total lymphocytes, total CD4+ and CD8+ T cells, B cells (absolute count) Total T cells, CD4+ cells (%) CD4+ CD28+ and CD8+ CD28+ T cells (%) CD86+ Dendritic cells (%)

      The BD FACSLyric™ Flow Cytometry System—A Next-Generation Flow Cytometer

      Built on a foundation of excellence, experience and expertise, the BD FACSLyric™ Flow Cytometry System is a new standard for cell analysis, transforming the way your lab does flow cytometry. As with all BD instruments, the BD FACSLyric™ Flow Cytometry System is backed by 40 years of BD expert training, service and support—so there’s no limit to your potential.

      Test

      This is a test

      TEXT AND DOWNLOAD SECTION
      TEXT AND DOWNLOAD TITLE
      prev
      next

      DESC1

      DESC1

      TT
      DP
      UV

      DESC2

      DESC2

      N2
      DP2
      UV2
      prev
      next
      DOWNLOADS

      TEXT AND IMAGE

      Website Feedback